Related Experiment Video
Updated: Jun 29, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Antibody responses after inactivated influenza vaccine in young children
Peter F Wright1, Edith Sannella, Jian R Shi
1Department of Pediatrics, Vanderbilt School of Medicine, Nashville, TN, USA. peter.wright@vanderbilt.edu
Insights
Antibody responses to trivalent inactivated influenza vaccine (TIV) in young children are sustained for months. This suggests protection throughout the influenza season following fall vaccination.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Antibody response duration and frequency after trivalent inactivated influenza vaccine (TIV) in young children are not well-defined.
- Expanded TIV recommendations for children aged 6 months to 5 years highlight the need for this data.
Purpose of the Study:
- To define the frequency and duration of antibody responses following TIV in young children.
- To assess the durability of immune responses in relation to the influenza season.
Main Methods:
- Forty-three children aged 6-23 months received TIV.
- Antibody responses were measured using hemagglutination inhibition (HAI) and neutralization assays.
- Antibody decay and duration were analyzed using sequential sera.
Main Results:
- Four-fold HAI rises were observed in 72% (H3N2), 92% (H1N1), and 60% (Influenza B) of naive children after two TIV doses.
- Antibody half-life (t1/2) was approximately 126 days for H1N1 and 258 days for H3N2.
- Microneutralization assay results correlated well with HAI findings.
Conclusions:
- While not all children achieved protective titers, antibody half-life suggests sustained immune responses.
- Children vaccinated in the fall likely maintain protective antibody levels throughout the influenza season.
Background:
The frequency and duration of antibody responses after trivalent inactivated influenza vaccine (TIV) in young children are not well defined and assume greater importance with the expanded recommendations for vaccine use in children aged 6 months-5 years.
Methods:
Forty-three children aged 6-23 months were vaccinated with TIV in the fall of 2002. At enrollment the majority of children were seronegative to one or more of the vaccine antigens and had no previously documented influenza. Postvaccination sera were collected in the subsequent fall and winter seasons. Acute antibody responses to TIV were determined using standardized hemagglutination inhibition (HAI) and neutralization assays. In calculating the duration of responses, sequential sera were analyzed to the last available sera, to the point at which antibody became undetectable, or to intercurrent influenza infection.
Results:
Forty-three subjects contributed 121 sera that were analyzed for HAI responses to TIV. Four-fold HAI rises after 2 doses of TIV in naive individuals were seen in 13 (72%) to H3N2, 22 (92%) to H1N1, and 15 (60%) to influenza B. Fewer 4-fold rises were seen in those with preexisting antibody. The results of microneutralization assays to H3N2 correlated well with HAI results. The time for antibody to decay to one-half of the postvaccination titer (t1/2) was approximately 126 days for H1N1 and 258 days for H3N2.
Conclusions:
Although not all children responded with 4-fold rises in antibody or achieved the putative protective titer of > or =1:32, the half-life of antibody suggested that children immunized in the fall should have immune responses sustained throughout the ensuing influenza season.
Related Concept Videos
Vaccinations
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Humoral Immune Responses
Cross-reactivity
Vaccines

